An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells

AIDS

Volumn 18, Issue 6, 2004, Pages 849-858

  Puri, Anu ^a   Rawat, Satinder S ^a   Lin, Han Ming Joseph ^a,d   Finnegan, Catherine M ^a   Mikovits, Judy ^c,e   Ruscetti, Francis W ^b   Blumenthal, Robert ^a,c  

^a Structural Glycobiology Section   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EpiGenX Pharmaceuticals Inc   (United States)

Author keywords

1 phenyl 2 hexadecanoylamino 3 morpholino 1 propanol (PPMP); CD4 lymphocytes; Gb3; Glycosphingolipids; GM3; HIV 1 infection; Membrane fusion

Indexed keywords

1 PHENYL 2 HEXADECANOYLAMINO 3 MORPHOLINO 1 PROPANOL; GAG PROTEIN; GANGLIOSIDE GM1; GANGLIOSIDE GM3; GLYCOSPHINGOLIPID; MORPHOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL FUSION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; MEMBRANE FUSION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; T LYMPHOCYTE; VIRUS ENVELOPE; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GLYCOSPHINGOLIPIDS; HIV CORE PROTEIN P24; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; MORPHOLINES; RECEPTORS, CXCR4; SPHINGOLIPIDS; VIRUS REPLICATION;

EID: 2142771723     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404090-00002     Document Type: Article

References (25)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
2. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999, 7:144-149.
3. Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, Wang JM, et al. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000, 74:6377-6385.
4. Ichikawa S, Hirabayashi Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 1998, 8:198-202.
5. Abe A, Inokuchi J, Jimbo M, Shimeno H, Nagamatsu A, Shayman JA, et al. Improved inhibitors of glucosylceramide synthase. J Biochem (Tokyo) 1992, 111:191-196.
6. Hammache D, Yahi N, Maresca M, Pieroni G, Fantini J. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 1999, 73:5244-5248.
7. Mahfoud R, Mylvaganam M, Lingwood CA, Fantini J. A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. J Lipid Res 2002, 43: 1670-1679.
8. Kiguchi K, Henning-Chubb CB, Huberman E. Glycosphingolipid patterns of peripheral blood lymphocytes, monocytes, and granulocytes are cell specific. J Biochem (Tokyo) 1990, 107:8-14.
9. Schwarting GA. Quantitative analysis of neutral glycosphingolipids from human lymphocyte subpopulations. Biochem J 1980, 189:407-412.
10. Marcus DM, Naiki M, Kundu SK. Abnormalities in the glycosphingolipid content of human Pk and p erythrocytes. Proc Natl Acad Sci USA 1976, 73:3263-3267.
11. Kijimoto-Ochiai S, Naiki M, Makita A. Defects of glycosyltransferase activities in human fibroblasts of Pk and p blood group phenotypes. Proc Natl Acad Sci USA 1977, 74:5407-5410.
12. Kundu SK, Suzuki A, Sabo B, McCreary J, Niver E, Harman R, et al. Erythrocyte glycosphingolipids of four siblings with the rare blood group p phenotype and their parents. J Immunogenet 1981, 8:357-365.
13. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
14. Kundu, S. K. Glycolipids: structure, synthesis, functions. In: Allen HJ, Kisailus EC (editors): Glycoconjugates, Composition, Structure, and Function. New York: Mark Dekker, Inc., 1992, pp. 203-262.
15. McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorino PM, Francis DP, et al. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods 1985, 76:171-183.
16. Earl PL, Koenig S, Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol 1991, 65:31-41.
17. Puri A, Paternostre M, Blumenthal R. Lipids in viral fusion. Methods Mol Biol 2002, 199:61-81.
18. Tuosto L, Parolini I, Schroder S, Sargiacomo M, Lanzavecchia A, Viola A. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001, 31:345-349.
19. Viard M, Parolini I, Sargiacomo M, Fecchi K, Ramoni C, Ablan S, et al. Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol 2002, 76:11584-11595.
20. Schaeffer E, Geleziunas R, Greene WC. Human immunodeficiency virus type 1 nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 2001, 75:2993-3000.
21. Sorice M, Garofalo T, Misasi R, Longo A, Mattei V, Sale P, et al. Evidence for cell surface association between CXCR4 and ganglioside GM3 after gp120 binding in SupT1 lymphoblastoid cells. FEBS Lett 2001, 506:55-60.
22. Fischer PB, Collin M, Karlsson GB, James W, Butters TD, Davis SJ, et al. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol 1995, 69:5791-5797.
23. Fischer PB, Karlsson GB, Butters TD, Dwek RA, Platt FM. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol 1996, 70:7143-7152.
24. 3. J Acquir Immune Defic Syndr 1994, 7:139-147.
25. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 1999, 274:14662-14669.